Alfacort

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alfacort

Quick Facts

Property Description
Active ingredient Hydrocortisone (or Hydrocortisone Acetate)
Form Cream, Ointment (topical dosage forms)
Pharmacological class Corticosteroid, Glucocorticoid
General purpose Anti-inflammatory and anti-itch relief for the skin
Origin Synthetic (chemically synthesized analog of cortisol)

Alfacort is a pharmaceutical preparation whose core identity is defined by its active ingredient, hydrocortisone, and its function as a topical corticosteroid. It is categorized as a single-active-ingredient product, primarily designed to deliver localized relief for various skin conditions.

What Type of Medicine is Alfacort?

Alfacort belongs to the pharmacological class of corticosteroids, and more specifically, is a glucocorticoid. This classification is recognized for its potent anti-inflammatory effects and signifies that the substance is structurally analogous to cortisol, a naturally occurring hormone that plays a crucial role in regulating immune and stress responses.

Unlike non-steroidal topical agents, Alfacort is typically positioned as a product for corticosteroid-responsive dermatoses. The drug is consistently formulated in topical dosage forms, such as a cream or ointment, intended for topical use and application directly to the skin surface. This method of delivery is designed to limit extensive systemic absorption when compared to oral or injectable steroid treatments, concentrating the effect where it is needed most.

Composition and Origin: Is Hydrocortisone Synthetic?

The principal component is hydrocortisone, which is chemically identical to the endogenous steroid cortisol (Compound F). Although its structure mirrors this natural substance, the active ingredient utilized in medicine is produced through controlled synthetic pharmaceutical processes to ensure high purity and standardization. The chemical profile of the synthesized drug confirms its potent anti-inflammatory properties for localized use.

In its common presentations, Alfacort uses hydrocortisone or its ester, hydrocortisone acetate, combined with an inert base/vehicle. This vehicle, such as an emulsified cream base or an oleaginous ointment base, is necessary to effectively carry the active ingredient and facilitate its absorption into the upper layers of the skin for a localized therapeutic effect. The specific formulation is often developed with suitability for sensitive skin in mind.

General Purpose and Core Physiological Action

The general purpose of Alfacort is to provide powerful, localized anti-inflammatory action and relief from itching. It achieves this by efficiently suppressing the body's overactive inflammatory response that causes visible symptoms like swelling, heat, and redness in the skin. This potent mechanism is fundamentally antipruritic, meaning it directly alleviates the bothersome pruritic manifestations (itching) often associated with conditions like insect bites or mild allergic reactions. By effectively controlling the localized inflammatory cascade, the product aims to facilitate patient comfort and enable the skin’s natural repair processes.

What side effects are possible with Alfacort?

Possible side effects and safety information

The official safety profile for Alfacort (topical hydrocortisone) is categorized by both local skin reactions and the potential for systemic adverse effects resulting from absorption, as documented in regulatory sources.

Local Skin Reactions and Frequency

Adverse reactions primarily involve the Skin and Subcutaneous Tissue Disorders system-organ class. Reactions such as burning, itching, irritation, and dryness are generally reported as occurring infrequently. Other local effects documented in official prescribing information include folliculitis, hypopigmentation (skin lightening), and skin atrophy (thinning), with the risk of the latter being linked to prolonged use.

Serious Systemic Effects

Although rare, systemic absorption can lead to serious risks involving the Endocrine System. Regulatory documents note the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing’s syndrome. These risks, along with the documented ocular risks of Glaucoma and Cataracts, are primarily associated with prolonged use or use on large surface areas.

Duration, Occlusion, and Special Populations

Safety constraints are explicitly tied to the method and duration of use. The use of occlusive dressings is documented to significantly increase systemic absorption, thereby amplifying the risk of serious endocrine effects. The official label also notes that pediatric patients (children and infants) are at a greater susceptibility to systemic adverse effects (HPA axis suppression) compared to adults, based on their skin surface area-to-body weight ratio.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents indicate that an acute overdose with topical Alfacort is unlikely. The primary overdose concern is the potential for excessive systemic absorption resulting from chronic misuse, prolonged use over large surface areas, or application under occlusive dressings.

Documented Overdose Manifestations Overuse can lead to manifestations of systemic steroid excess, known as hypercorticism, which may resemble Cushing's syndrome. This condition is primarily associated with Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, a potentially reversible condition. Other documented signs include hyperglycemia and glucosuria. If the medication is stopped abruptly after prolonged overuse, symptoms of steroid withdrawal may also occur.

Urgent Medical Attention Required The regulatory guidance emphasizes that immediate medical attention must be sought in cases of suspected adrenal insufficiency or adrenal crisis, which is a severe consequence of HPA axis suppression. Patients using the product over a large area or for prolonged periods must be evaluated periodically for evidence of HPA axis suppression, often utilizing the ACTH stimulation test.

Overdose Management and Risk Notes No specific antidote for hydrocortisone overdose is documented. Management consists of symptomatic and supportive treatment. Pediatric patients are identified as being at greater risk for systemic effects, including HPA axis suppression and, rarely, intracranial hypertension, due to their higher skin surface area-to-body weight ratio.

Therapeutic Uses of Alfacort

What Alfacort Treats: Main Uses and Benefits

Alfacort (topical hydrocortisone) is applied across the domain of corticosteroid-responsive dermatoses—a class of conditions involving inflammatory or irritative processes in the skin. This medicine is used to help manage symptoms related to redness, swelling, itching, and discomfort of various skin conditions, aligning with its core therapeutic scope.

It is commonly used to help with conditions characterized by periods of heightened symptoms, such as different types of eczema (like atopic and contact dermatitis), psoriasis patches, and acute contact dermatitis. This class of medication is used to provide supportive relief when symptoms interfere with routine activities and general comfort.

The medication is applied in addressing symptoms related to inflammatory or irritative states, with the primary benefit being localized symptomatic relief from the distressing symptoms of itching (pruritus), redness (erythema), and swelling. It provides support that helps ease the overall symptom burden, particularly when these manifestations create noticeable physiological strain.

It is relevant when short-term symptomatic assistance is needed, such as managing acute local reactions from common insect bites or minor skin irritation. It may assist with maintaining functional stability during symptomatic phases and is commonly used across patient groups, including for inflammation in sensitive areas like the diaper area in infants.


Quick Fact: Relief for Inflammatory Skin Manifestations The core therapeutic role is to offer supportive relief from the combined effects of inflammation and itching (pruritus) in common acute and recurrent skin conditions, helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Alfacort, which contains the corticosteroid hydrocortisone, has specific eligibility rules established in official regulatory documents that define who can and cannot use the medicine.

Populations for Whom Use is Restricted or Contraindicated

The most stringent restrictions are contraindications, which prohibit use in certain patient groups:

  • Hypersensitivity: Patients with a known allergy or hypersensitivity to hydrocortisone or any of the inactive ingredients in the preparation must not use this medicine.
  • Existing Infections: Use is contraindicated when specific untreated skin infections are present at the application site. This includes viral infections (e.g., herpes simplex, chickenpox), fungal, or bacterial infections, as the corticosteroid may worsen these conditions or mask symptoms.
  • Specific Dermatoses: The medicine is typically contraindicated for conditions such as rosacea and perioral dermatitis.

Use is not recommended or requires special caution in other populations due to an increased risk of systemic absorption and related effects:

Population Eligibility Classification/Restriction
Pediatric Patients Use in children, especially those under two years of age, is generally not recommended or should be limited to the least effective amount and duration. Children have a larger skin surface area to body weight ratio, increasing susceptibility to side effects like HPA axis suppression and Cushing's syndrome.
Pregnancy Classified as Pregnancy Category C by the FDA. Use should be considered only if the potential benefit outweighs the risk to the fetus, and the medicine should not be used extensively, in large amounts, or for prolonged periods.
Specific Systemic Conditions Caution is advised for patients with pre-existing conditions such as Cushing's syndrome or diabetes, as systemic absorption may exacerbate these disorders.

Occlusive dressings (e.g., bandages, tight-fitting diapers) over the application area are an eligibility restriction, as they significantly increase systemic absorption and the potential for adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions officially documented in regulatory information for Alfacort (Dabigatran Etexilate), focusing on agents that significantly alter systemic exposure or increase bleeding risk.

Interaction Scope

Category Regulatory Statement Summary
Medicinal product categories with documented interactions: P-glycoprotein (P-gp) Inhibitors, P-glycoprotein (P-gp) Inducers, Other Anticoagulants, Anti-platelet Agents, Non-Steroidal Anti-inflammatory Drugs (NSAIDs).
Mechanistic basis of interactions (only if stated in label): Modulation of systemic exposure via the P-glycoprotein (P-gp) efflux transporter. Concomitant use with other drugs that affect hemostasis increases risk of bleeding.
Population-specific interaction notes (if applicable): Renal Impairment (Creatinine Clearance, CrCl) status is a factor defining restrictions for co-administration with P-gp inhibitors.

Interaction-Related Restrictions and Constraints

Regulatory documents stipulate that co-administration with P-gp inducers (e.g., Rifampin) should generally be avoided due to reduced drug exposure. Co-administration with P-gp inhibitors is restricted in patients with specific degrees of renal impairment. The concomitant use of Alfacort with other medications that increase the risk of bleeding, such as anti-platelet agents and NSAIDs, is an officially listed risk factor for hemorrhage that requires professional monitoring. When converting a patient from warfarin, the initiation of Alfacort is constrained by the patient's International Normalized Ratio (INR) being below 2.0. The overall interaction profile is primarily defined by the drug’s role as a P-gp substrate.

Mechanism of Action

The mechanism of action for Hydrocortisone is centered on its role as a Glucocorticoid Receptor ( GR) agonist, modulating the body's local inflammatory response by altering genetic instruction within skin cells. The primary action involves binding to the GR inside target cells, which then translocates to the nucleus to directly regulate DNA activity. This genomic mechanism simultaneously turns off (transrepression) the genes responsible for generating major pro-inflammatory signals like cytokines and turns on (transactivation) the production of anti-inflammatory proteins, resulting in localized suppression of the immune response in the dermal tissue. . By inducing anti-inflammatory proteins, the mechanism leads to the inhibition of the enzyme Phospholipase A2 ( PLA2), which inhibits the Arachidonic Acid Cascade and limits the formation of inflammatory lipid mediators, including prostaglandins and leukotrienes. This reduces the chemical triggers for edema, erythema, and pruritus pathway activity. Furthermore, the drug regulates local immune cell activity and induces localized vasoconstriction, reducing microvascular permeability and local fluid accumulation.

Dosage and Administration Information

How to Use Alfacort

Alfacort, a topical hydrocortisone preparation, is applied to the skin following administration guidelines, which define the correct route, dosage application, frequency, and duration of use. Its administration is characterized by a topical-only route, being available in various strengths (0.1% to 2.5%) across forms such as a cream, ointment, or lotion.


Official Usage Principles

Usage Constraint Guideline
Route & Dose Strictly for external use only. Apply a thin film gently to the affected skin area, ensuring hands are washed before and after application.
Frequency Application is typically two to four times daily for adults, though some higher-strength formulations may specify less frequent use.
Duration The course of therapy should be as short as possible. For self-managed conditions, use should generally not exceed seven days without professional guidance. Treatment should be discontinued once control is achieved.

Administration Requirements and Restrictions

Guidelines emphasize constraints designed to control the rate of absorption. The treated area must not be bandaged, covered, or wrapped (occlusive dressing) unless explicitly directed by a healthcare provider. This restriction is in place to prevent excessive systemic absorption of the active ingredient. Additionally, contact with the eyes, mouth, and other mucous membranes must be avoided.

For pediatric patients, use must be strictly limited to the least amount compatible with effective therapy. In infants and children, the duration of use is generally recommended not to exceed seven to ten days. In cases of a missed application, the dose should be applied as soon as it is remembered; however, patients are instructed not to double the dose to compensate for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alfacort (Topical Hydrocortisone)


Evidence Base Overview: Types of Studies Available

The research foundation for Alfacort (topical hydrocortisone) is drawn from a large body of official research that includes both randomized controlled trials (RCTs) and comprehensive systematic reviews and meta-analyses. These studies were studied for and are considered in defining the areas for which it was studied. Regulatory bodies also rely on specific clinical pharmacology studies, such as the vasoconstrictor assay, which studies monitored as an indicator of physiological response. This collective evidence contributes to the broader evidence landscape. The findings describe patterns observed in these studies, focusing on conditions characterized by fluctuating or episodic manifestations in the skin.


Evidence for Use in Atopic Dermatitis (Eczema)

Research exploring short-term symptom patterns in eczema primarily involves short-term, placebo-controlled RCTs, supported by aggregated data from systematic reviews. In these trials, Alfacort was evaluated in adults and children with mild to moderate disease severity. The main outcomes related to physical discomfort that research examined included changes in disease severity scales (EASI, IGA) and monitored patient-reported outcomes describing perceived discomfort, such as measurements related to changes in pruritus (itching) and changes in visible redness.

Findings describe patterns observed in these short-term studies, where data related to symptom intensity were reported over defined time intervals, typically lasting a few weeks. The evidence contributes to understanding symptom patterns during periods of heightened symptom activity. The evidence quality varies across studies, particularly for older trials. Research explores short-term symptom patterns, but the studies provide limited insight into long-term effects.


Evidence for Use in Contact Dermatitis

The evidence for Alfacort in contact dermatitis was studied for its application in conditions associated with acute or disruptive episodes, particularly where symptoms become more noticeable. Research has explored outcomes linked to inflammatory or irritative states, such as measurements of change in visible inflammation. Study designs include RCTs and specific experimental human volunteer studies where irritation was observed in controlled settings.

Findings indicate that studies reported how symptoms evolved in the observed populations with allergic contact dermatitis, often showing measurements related to changes in inflammatory signs over short follow-up durations. For the specific context of irritant contact dermatitis, the data show patterns related to varying symptom burdens. Evidence appears limited for this use, and findings were mixed across systematic reviews, suggesting that certainty remains low for this context.


Evidence in Special Populations

The existing research base primarily focuses on generally healthy adults and children with mild-to-moderate eczema. For certain subgroups, data for certain groups remain insufficient. Specifically, while use in children with eczema was studied for, the evidence provides limited information for long-term outcomes in very young age groups, such as infants. Long-term effects are not fully established for these groups, and results apply only to the populations studied. Data for certain groups defined by other comorbid conditions remain insufficient.


Long-Term Studies and Follow-up

The majority of the available, high-quality RCTs that studies explored for efficacy have follow-up durations that were limited, typically lasting only between one and six weeks. Research highlights changes measured during the study period, but this restricted duration means that long-term effects are not fully established. There is limited information for long-term outcomes regarding the durability of symptom control or the frequency of disease relapse over many months or years. The evidence remains limited and heterogeneous regarding long-term effects beyond the studied follow-up durations.


What is Still Uncertain in the Research

Despite the existence of a substantial evidence base, research highlights what is known and what is still uncertain about Alfacort. Comparative evidence is lacking in some areas. The initial research often employed small sample sizes, and evidence quality varies across studies, particularly for older trials. Data are still emerging for certain subgroups and long-term consequences, highlighting remaining areas of uncertainty.

Key Studies & References Topical corticosteroids for atopic dermatitis (eczema) - Clinical guideline review covering efficacy and safety data

Frequently Asked Questions (FAQ)

Common questions about Alfacort (FAQ)


Q: Can Alfacort be used for skin conditions other than what's on the label?

A: Topical hydrocortisone is indicated for conditions known as corticosteroid-responsive dermatoses. Regulatory information specifies that the medicine should be used only for the conditions for which it was prescribed or recommended by a healthcare provider. This is because the effectiveness and safety of the medicine have not been established for off-label uses.


Q: What are the most common side effects people report with Alfacort?

A: Regulatory documents report that common local adverse reactions can include temporary skin burning, itching, irritation, or dryness at the application site. More serious side effects, known as systemic effects, are rare; they are primarily associated with high absorption resulting from prolonged or extensive use.


Q: Does Alfacort cause weight gain if used for a long time?

A: Official information indicates that prolonged or extensive use leading to high systemic absorption has been associated with endocrine system changes. These effects include symptoms associated with Cushing’s syndrome, which can involve changes in the way the body stores fat.


Q: Is Alfacort approved for treating eczema?

A: Topical hydrocortisone is officially indicated for the temporary relief of inflammation and itching. This includes rashes associated with corticosteroid-responsive skin conditions such as eczema (also known as atopic dermatitis).


Q: What are the main ingredients in Alfacort besides the active substance?

A: The medication contains the active ingredient, hydrocortisone, combined with a non-medicinal base. According to official documents, these non-medicinal ingredients can include substances like purified water, cetyl alcohol, glycerin, and propylene glycol, which help carry the active substance and facilitate application.


Q: How does the concentration of Alfacort affect how strong it is?

A: The strength, or potency, of the medicine is directly related to the concentration of hydrocortisone, which can range from low (0.1%) to higher (2.5%) amounts. Official information indicates that higher concentrations may result in a greater effect. The final potency is also influenced by the specific formulation, such as whether it is a cream or an ointment.


Q: What does 'topical use only' mean for Alfacort?

A: Topical use means the medication is strictly for external application directly to the skin surface. Official product information specifies that the medicine must not be used internally or come into contact with the eyes, mouth, or other sensitive mucous membranes.


Q: What are the results of the key research studies on Alfacort?

A: Regulatory approval for topical hydrocortisone is based on clinical studies and specialized testing, such as the vasoconstrictor assay. These studies demonstrate its localized anti-inflammatory and anti-itch actions in the short term. Official research summaries state that evidence for long-term effects beyond the studied follow-up durations remains limited.


Q: Can Alfacort be used by people with kidney problems?

A: Systemic absorption of the drug, although low, may potentially cause fluid retention. Regulatory warnings mention that the use of this type of medicine requires caution when a patient has a pre-existing condition such as renal dysfunction (kidney problems).


Q: What does the patient information leaflet say about stopping the medicine?

A: Regulatory guidance advises that discontinuation, particularly after using the medicine for prolonged periods or in large amounts, may be associated with a risk of a withdrawal reaction. This may involve symptoms like severe redness and burning in the treated area.


Q: Is there a difference in efficacy based on the vehicle (cream vs. ointment)?

A: Official guidance states that ointments are generally considered to provide greater absorption and potentially higher efficacy than the same concentration in a cream form. This difference is due to the occlusive barrier that ointments create on the skin. The final choice of vehicle is based on the specific condition being addressed.


Q: What is the difference between Alfacort cream and ointment?

A: Ointments are typically oil-based, providing an occlusive barrier that is often better suited for skin areas that are very dry or thickened. Creams, conversely, are water-and-oil emulsions and are generally preferred for moist or weeping skin conditions due to their less occlusive nature.


Q: Is there a risk of withdrawal when stopping Alfacort?

A: Regulatory guidance advises that discontinuation, particularly after using the medicine for prolonged periods or in large amounts, may be associated with a risk of a withdrawal reaction. This may involve symptoms like severe redness and burning in the treated area.


Q: Do I need a prescription from a doctor for Alfacort?

A: Official product information confirms that topical hydrocortisone is available in both over-the-counter (OTC) and prescription (Rx) strengths. The classification depends on the specific concentration and overall formulation of the product being used.


Q: Are there any known food or drink interactions with Alfacort?

A: Regulatory documents note that the active ingredient, hydrocortisone, has documented interactions with alcohol and specific foods when taken orally (systemically). Given that topical absorption is limited, patients should consult the patient leaflet or a healthcare provider for specific information regarding consumption while using the medicine.


Q: Can Alfacort interact with herbal supplements like St. John's Wort?

A: Official regulatory guidance suggests that topical medicines like this one, which have limited systemic absorption, are generally not likely to interact with herbal supplements such as St. John's Wort.


Q: What are the signs that Alfacort is not working for my condition?

A: Regulatory instructions advise seeking professional guidance if the condition does not show signs of improvement within a few days of use. Patients are instructed to consult a healthcare provider if symptoms suddenly become worse or if new symptoms develop.


Q: How long after opening should I throw away the Alfacort tube?

A: Regulatory documents require a manufacturer's expiration date to be stamped on the tube or outer packaging. The medication should be discarded after this date. The product should also be discarded if there are any visual signs of contamination or damage.


Q: Can I apply makeup or moisturizer over Alfacort?

A: Regulatory precautions state that cosmetics or other general skin care products, such as makeup or moisturizers, should not be used on the treated area. This is because these products may interfere with the medicine's effectiveness or increase absorption.


Q: Why is it restricted for use on certain body areas?

A: The medicine is restricted from use around the eyes and on large areas of the body due to the risk of increased systemic absorption or specific side effects. Furthermore, official guidance advises against using occlusive forms, like ointments, in skin folds due to an increased risk of local adverse reactions.


Q: Can Alfacort be used on open cuts or broken skin?

A: Regulatory instructions for proper use clearly advise against applying the medication to any skin areas that have open cuts, scrapes, or burns. This is a standard safety precaution to limit absorption and avoid potential adverse reactions.


Q: Are there specific warnings about Alfacort for elderly patients?

A: Official regulatory information notes that specific data relating the age of geriatric patients to the effects of topical hydrocortisone is not available. Regulatory information provides no specific data regarding this population.


Q: Does Alfacort contain any ingredients sourced from animals?

A: The active ingredient, hydrocortisone, is defined as a synthetic substance. While the inactive ingredients used in the base are listed in the official documents, their specific source (animal or vegetable) is not typically detailed in regulatory information.

How should Alfacort be stored and disposed of?

How to Store and Dispose of Alfacort (Hydrocortisone)

The storage and disposal of Alfacort, a topical hydrocortisone product, must adhere strictly to regulatory guidelines to ensure stability and safety.

Storage Requirements

Hydrocortisone topical products must be stored at Controlled Room Temperature, typically between 20 C to 25 C (68 F to 77 F).

  • Protection: It is mandatory to protect from freezing and store away from excess heat and moisture.
  • Container: Keep the container tightly closed and store the medication in the container it came in.
  • Child Safety: Keep this and all medications out of the sight and reach of children.

Disposal Instructions

  • Preferred Method: Unused or expired medication should be taken to a drug take-back program.
  • Alternative: If a take-back program is unavailable, mix the medicine with an undesirable substance (like coffee grounds or kitty litter) and place the mixture in a sealed container before throwing it in the household trash. Do not flush Alfacort down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alfacort found in:

A-Z Index: